David Lillicrap

List of Publications by Year in descending order

142 papers	2,993 citations	201385 27 h-index	189595 50 g-index
239 all docs	239 docs citations	239 times ranked	3169 citing authors

#	Article	IF	Citations
1	The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood, 2007, 109, 145-154.	0.6	310
2	Disseminated intravascular coagulation in patients with 2019â€nCoV pneumonia. Journal of Thrombosis and Haemostasis, 2020, 18, 786-787.	1.9	264
3	Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ, The, 2021, 375, n2400.	3.0	250
4	The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood, 2007, 109, 145-154.	0.6	210
5	von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood, 2013, 122, 3735-3740.	0.6	147
6	Variation at the von Willebrand Factor (vWF) Gene Locus Is Associated With Plasma vWF:Ag Levels: Identification of Three Novel Single Nucleotide Polymorphisms in the vWF Gene Promoter. Blood, 1999, 93, 4277-4283.	0.6	110
7	Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood, 2016, 127, 2481-2488.	0.6	96
8	Advances and challenges for hemophilia gene therapy. Human Molecular Genetics, 2019, 28, R95-R101.	1.4	73
9	The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity. Journal of Clinical Investigation, 2018, 128, 4057-4073.	3.9	67
10	Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. Cellular Immunology, 2016, 301, 30-39.	1.4	53
11	Tolerating Factor VIII: Recent Progress. Frontiers in Immunology, 2019, 10, 2991.	2.2	52
12	Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report. HemaSphere, 2019, 3, e286.	1.2	43
13	Hemophilia Gene Therapy: Approaching the First Licensed Product. HemaSphere, 2021, 5, e540.	1.2	40
14	Randomized trials of therapeutic heparin for COVIDâ€19: A metaâ€analysis. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12638.	1.0	39
15	Von Willebrand diseaseâ€”Phenotype versus genotype: Deficiency versus disease. Thrombosis Research, 2007, 120, S11-S16.	0.8	38
16	Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. Blood, 2017, 129, 3147-3154.	0.6	38
17	Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity. Haematologica, 2015, 100, 149-156.	1.7	37
18	von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Hematology American Society of Hematology Education Program, 2013, 2013, 254-260.	0.9	35

#	Article	IF	Citations
19	A past mutation at Isoleucine397is now a common cause of moderate/mild haemophilia B. British Journal of Haematology, 1990, 75, 212-216.	1.2	34
20	Improvements in factor concentrates. Current Opinion in Hematology, 2010, 17, 393-397.	1.2	34
21	Comparative pharmacokinetics of two extended halfâ€life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?. Journal of Thrombosis and Haemostasis, 2019, 17, 1085-1096.	1.9	34
22	Assembly of alternative prothrombinase by extracellular histones initiates and disseminates intravascular coagulation. Blood, 2021, 137, 103-114.	0.6	33
23	The endothelial lectin clearance receptorCLEC4M binds and internalizes factorVIIIin aVWFâ€dependent and independent manner. Journal of Thrombosis and Haemostasis, 2019, 17, 681-694.	1.9	32
24	A Novel Cell-Sheet Technology That Achieves Durable Factor VIII Delivery in a Mouse Model of Hemophilia A. PLoS ONE, 2013, 8, e83280.	1.1	31
25	Severe haemophilia A in a female resulting from two de novo factor VIII mutations. British Journal of Haematology, 1995, 90, 906-909.	1.2	29
26	Multiplex analysis of two intragenic microsatellite repeat polymorphisms in the genetic diagnosis of haemophilia A. British Journal of Haematology, 1994, 86, 810-815.	1.2	28
27	Extending half-life in coagulation factors: where do we stand?. Thrombosis Research, 2008, 122, S2-S8.	0.8	28
28	Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response. Blood, 2014, 123, 4045-4053.	0.6	28
29	Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A. Blood, 2016, 127, 3439-3449.	0.6	27
30	Analysis of the role of von Willebrand factor, platelet glycoprotein VI-, and Î±2Î²1-mediated collagen binding in thrombus formation. Blood, 2014, 124, 1799-1807.	0.6	26
31	Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia. Blood, 2018, 131, 2205-2214.	0.6	26
32	Advances in knowledge of inhibitor formation in severe haemophilia A. British Journal of Haematology, 2020, 189, 39-53.	1.2	25
33	N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice. Haematologica, 2018, 103, 1925-1936.	1.7	23
34	von Willebrand Factor Is a Critical Mediator of Deep Vein Thrombosis in a Mouse Model of Diet-Induced Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2860-2874.	1.1	23
35	The â^'1185 A/G and â^'1051 G/A dimorphisms in the von Willebrand factor gene promoter and risk of myocardial infarction. British Journal of Haematology, 2001, 115, 701-706.	1.2	19
36	Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Trials, 2021, 22, 202.	0.7	19

#	Article	IF	Citations
37	Recurring mutations at CpG dinucleotides in the region of the von Willebrand factor gene encoding the glycoprotein Ib binding domain, in patients with type IIB von Willebrand's disease. British Journal of Haematology, 1991, 79, 612-617.	1.2	18
38	Endothelial characteristics in healthy endothelial colony forming cells; generating a robust and valid ex vivo model for vascular disease. Journal of Thrombosis and Haemostasis, 2020, 18, 2721-2731.	1.9	18
39	Positive Immunoglobulin Gene Rearrangement Study by the Polymerase Chain Reaction in a Colonic Adenocarcinoma. American Journal of Clinical Pathology, 1992, 98, 116-119.	0.4	17
40	Gene Therapy for Coagulation Disorders. Circulation Research, 2016, 118, 1443-1452.	2.0	17
41	The scavenger receptor SCARA5 is an endocytic receptor for von Willebrand factor expressed by littoral cells in the human spleen. Journal of Thrombosis and Haemostasis, 2019, 17, 1384-1396.	1.9	17
42	To clot or not to clot? Ad is the questionâ€”Insights on mechanisms related to vaccineâ€induced thrombotic thrombocytopenia. Journal of Thrombosis and Haemostasis, 2021, 19, 2845-2856.	1.9	16
43	Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms. Expert Review of Hematology, 2020, 13, 313-321.	1.0	15
44	Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. Haemophilia, 2020, 26, 443-449.	1.0	15
45	Multimerin 1 supports platelet function in vivo and binds to specific GPAGPOGPX motifs in fibrillar collagens that enhance platelet adhesion. Journal of Thrombosis and Haemostasis, 2021, 19, 547-561.	1.9	15
46	Gene therapy for hemophilia: Current status and laboratory consequences. International Journal of Laboratory Hematology, 2021, 43, 117-123.	0.7	15
47	The Role of Immunomodulation in the Management of Factor VIII Inhibitors. Hematology American Society of Hematology Education Program, 2006, 2006, 421-425.	0.9	14
48	Cardiac decellularisation with longâ€term storage and repopulation with canine peripheral blood progenitor cells. Canadian Journal of Chemical Engineering, 2012, 90, 1457-1464.	0.9	14
49	The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance. Blood Advances, 2018, 2, 1585-1594.	2.5	14
50	Hemophilia gene therapy knowledge and perceptions: Results of an international survey. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 644-651.	1.0	14
51	Rapid genotype analysis in type 2B von Willebrand's disease using a universal heteroduplex generator. British Journal of Haematology, 1995, 89, 152-156.	1.2	13
52	War and peace: Factor VIII and the adaptive immune response. Cellular Immunology, 2016, 301, 2-7.	1.4	13
53	To clear or to fear: An innate perspective on factor VIII immunity. Cellular Immunology, 2016, 301, 82-89.	1.4	13
54	A sticky proposition: The endothelial glycocalyx and von Willebrand factor. Journal of Thrombosis and Haemostasis, 2020, 18, 781-785.	1.9	13

#	Article	IF	Citations
55	Genetically-Engineered Endothelial Cells Implanted Into the Omentum of Hemophilia A Dogs Provides Long-Term Circulating FVIII Resulting From Sustained FVIII Expression and Persistent Cell Viability.. Blood, 2009, 114, 3578-3578.	0.6	13
56	A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects. Thrombosis and Haemostasis, 2021, 121, 1326-1336.	1.8	12
57	The challenge of genetically unresolved haemophilia A patients: Interest of the combination of whole F8 gene sequencing and functional assays. Haemophilia, 2020, 26, 1056-1063.	1.0	11
58	Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population. Journal of Thrombosis and Haemostasis, 2021, 19, 654-663.	1.9	11
59	Utility of factor VIII and factor VIII to von Willebrand factor ratio in identifying 277 unselected carriers of hemophilia A. American Journal of Hematology, 2017, 92, E94-E96.	2.0	10
60	Bispecific Antibody Therapy in Hemophilia. New England Journal of Medicine, 2017, 377, 884-885.	13.9	9
61	Evaluating the potential benefits of the extravascular pool of factor IX. Blood Coagulation and Fibrinolysis, 2021, 32, 68-69.	0.5	8
62	Role of von Willebrand factor in venous thromboembolic disease. JVS Vascular Science, 2022, 3, 17-29.	0.4	8
63	In Vitro and In Vivo Mouse Models of the Type 1 Von Willebrand Disease Mutations Y1584C and R1205H.. Blood, 2009, 114, 26-26.	0.6	8
64	Androgen effects on factor IX expression:inâ€vitroandinâ€vivostudies in mice. British Journal of Haematology, 1998, 101, 273-279.	1.2	7
65	FIX It in One Go: Enhanced Factor IX Gene Therapy for Hemophilia B. Cell, 2017, 171, 1478-1480.	13.5	7
66	Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms. Haematologica, 2018, 103, 1403-1413.	1.7	7
67	Functional Roles of the von Willebrand Factor Propeptide. Hamostaseologie, 2021, 41, 063-068.	0.9	7
68	Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation. Journal of Visualized Experiments, 2017, , .	0.2	6
69	Fifty years new. Journal of Thrombosis and Haemostasis, 2019, 17, 1-1.	1.9	6
70	Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcÎ³RIIB Receptor. Frontiers in Immunology, 2020, 11, 138.	2.2	6
71	The Complete Type I VWD Cohort Of The Zimmerman Program For The Molecular and Clinical Biology Of VWD - Phenotypic Assignment, Mutation Frequency, and Bleeding Assessment. Blood, 2013, 122, 332-332.	0.6	6
72	Mouse Models of the Common, Recurring Type 1 von Willebrand Disease Mutations Y1584C and R1205H. Blood, 2010, 116, 22-22.	0.6	6

#	Article	IF	Citations
73	Gene Expression: Overview and Clinical Implications. Vox Sanguinis, 2002, 83, 77-79.	0.7	5
74	Shear stress and platelet-induced tensile forces regulate ADAMTS13-localization within the platelet thrombus. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 254-260.	1.0	5
75	The highly prevalent deletions in F8 intron 13 found in French mild hemophilia A patients result from both founder effect and recurrent de novo events. Journal of Thrombosis and Haemostasis, 2020, 18, 1087-1093.	1.9	5
76	Surgical Injury Alone Does Not Provoke the Development of Factor VIII Inhibitors in Mouse Models of Hemophilia A. Blood, 2012, 120, 627-627.	0.6	5
77	Longitudinal bleeding assessment in von willebrand disease utilising an interim bleeding score. Journal of Thrombosis and Haemostasis, 0, , .	1.9	5
78	The future of hemostasis management. Pediatric Blood and Cancer, 2013, 60, S44-7.	0.8	4
79	COVIDâ€19: 2020 a year in turmoil. Journal of Thrombosis and Haemostasis, 2020, 18, 993.	1.9	4
80	Molecular coevolution of coagulation factor VIII and von Willebrand factor. Blood Advances, 2021, 5, 812-822.	2.5	4
81	The Endothelial Lectin Receptor CLEC4M Internalizes Factor VIII and Von Willebrand Factor Via a Clathrin-Coated Pit-Dependent Mechanism. Blood, 2013, 122, 1091-1091.	0.6	4
82	Multifaceted pathomolecular mechanism of a VWF large deletion involved in the pathogenesis of severe VWD. Blood Advances, 2022, 6, 1038-1053.	2.5	4
83	von Willebrand factor propeptide variants lead to impaired storage and ER retention in patientâ€derived endothelial colonyâ€forming cells. Journal of Thrombosis and Haemostasis, 2022, 20, 1599-1609.	1.9	4
84	Von Willebrand Disease. , 0, , 51-61.		3
85	The World Federation of Hemophilia and research. Haemophilia, 2012, 18, 24-27.	1.0	3
86	Innovative Molecular Testing Strategies for Adjunctive Investigations in Hemostasis and Thrombosis. Seminars in Thrombosis and Hemostasis, 2019, 45, 751-756.	1.5	3
87	Genetic Variability of the CLEC4M Endothelial Lectin Receptor Modulates Binding and Internalization of Von Willebrand Factor and Contributes to Variance in Plasma VWF Levels. Blood, 2012, 120, 16-16.	0.6	3
88	Immune-Modulatory Effects of Mesenchymal Stromal Cell Infusions for the Treatment of Factor VIII Inhibitor in Hemophilia A.. Blood, 2009, 114, 1299-1299.	0.6	3
89	A Modified Model of Type 2B von Willebrand Disease: Taking ADAMTS13-Mediated Cleavage out of the Equation. Blood, 2010, 116, 23-23.	0.6	3
90	Application of in-vitro-cultured primary hepatocytes to evaluate species translatability and AAV transduction mechanisms of action. Molecular Therapy - Methods and Clinical Development, 2022, 26, 61-71.	1.8	3

#	Article	IF	Citations
91	Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15033.	1.8	2
92	Thrombolytic Potential of N -Acetylcysteine. Circulation, 2017, 136, 661-663.	1.6	2
93	Changes. Journal of Thrombosis and Haemostasis, 2020, 18, 1-1.	1.9	2
94	2020 â€“ Year of COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 2081-2081.	1.9	2
95	Functional characterisation of the type 1 von Willebrand disease candidate VWF gene variants: p.M771I, p.L881R and p.P1413L. Blood Transfusion, 2017, 15, 548-556.	0.3	2
96	Basic Principles Underlying the Coagulation System. , 0, , 1-7.		1
97	Qualitative Platelet Disorders. , 0, , 83-90.		1
98	Hepatology. , 0, , 182-189.		1
99	Laboratory Tests of Hemostasis. , 0, , 8-17.		1
100	Gut dysbiosis modulates the immune response to factor VIII in murine hemophilia A. Blood Advances, 2020, 4, 2644-2655.	2.5	1
101	Hemostasis and thrombosis 101â€”A challenge to energize. Journal of Thrombosis and Haemostasis, 2020, 18, 269-269.	1.9	1
102	The diagnosis of a haemophilia A carrier over 2 decades. Haemophilia, 2021, 27, e133-e136.	1.0	1
103	Quantitation of Changes in VWF and FVIII Following Elective Orthopedic Surgery in Normal Individuals.. Blood, 2009, 114, 1296-1296.	0.6	1
104	Regulation Of Factor VIII Clearance By Mannose-Binding Lectins. Blood, 2013, 122, 2340-2340.	0.6	1
105	Differential Glycosylation Between Recombinant Factor VIII Produced in Baby Hamster Kidney and Chinese Hamster Ovary Cells Confers Differences in Immunogenicity in a Humanized Hemophilia Î‘ Mouse Model. Blood, 2016, 128, 326-326.	0.6	1
106	Development of an Optimized rAAV2/6 Human Factor 8 cDNA Vector Cassette for Hemophilia a Gene Therapy. Blood, 2016, 128, 1173-1173.	0.6	1
107	Low von Willebrand factor phenotype: the enigma continues. Blood, 2022, 139, 2102-2103.	0.6	1
108	Appendices: Normal Ranges. , 0, , 209-213.		0

#	Article	IF	Citations
109	Disseminated Intravascular Coagulation and other Microanjiopathies. , 0, , 91-100.		0
110	Arterial Thrombosis. , 0, , 114-119.		0
111	Anticoagulation. , 0, , 120-129.		0
112	Intensive/Critical Care. , 0, , 158-171.		0
113	Cardiothoracic Surgery. , 0, , 172-181.		0
114	Transfuction. , 0, , 201-208.		0
115	Hemophilia A and B. , 0, , 39-50.		0
116	The Rarer Inherited Coagulation Disorders. , 0, , 62-68.		0
117	Quantitative Platelet Disorders. , 0, , 69-82.		0
118	Appendices: Useful Websites. , 0, , 214-215.		0
119	Tests of Platelet Function. , 0, , 29-38.		0
120	Foreword. European Journal of Haematology, 2015, 95, 1-1.	1.1	0
121	Genomic momentum for hemostasis and thrombosis. Journal of Thrombosis and Haemostasis, 2019, 17, 1411-1411.	1.9	0
122	Abstract thoughts of hemostasis. Journal of Thrombosis and Haemostasis, 2019, 17, 245-245.	1.9	0
123	Challenges in diagnosis of von Willebrand disease in the presence of combined mutations of different genes. Haemophilia, 2019, 25, e113-e117.	1.0	0
124	Simplify, simplify. Journal of Thrombosis and Haemostasis, 2019, 17, 711-711.	1.9	0
125	A virtual ISTH Congress. Journal of Thrombosis and Haemostasis, 2020, 18, 1237-1237.	1.9	0
126	The end of an extraordinary year. Journal of Thrombosis and Haemostasis, 2020, 18, 3129-3129.	1.9	0

#	Article	IF	Citations
127	Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII. Frontiers in Immunology, 2020, 11, 150.	2.2	0
128	Changes for 2021. Journal of Thrombosis and Haemostasis, 2021, 19, 1-1.	1.9	0
129	Evidenceâ€based medicine in thrombosis and hemostasis: ISTH to the fore. Journal of Thrombosis and Haemostasis, 2021, 19, 1845-1846.	1.9	0
130	Results of a World Wide Survey On the Diagnostic Dilemma Between Type 2B Von Willeband Disease and the PT-VWD.. Blood, 2009, 114, 4436-4436.	0.6	0
131	Investigation of the Role of Copy Number Variation In the Pathogenesis of Type 1 Von Willebrand Disease. Blood, 2010, 116, 2218-2218.	0.6	0
132	Comprehensive In Vitro and In Vivo Characterization of Loss and Gain-of-Function Von Willebrand Factor Collagen Binding Variants Using a Mouse Model System,. Blood, 2011, 118, 3266-3266.	0.6	0
133	Ten-Year Canadian National Prospective Data On Utilization of Anti-Hemophilic Concentrates: Indications and Trends. Blood, 2012, 120, 1186-1186.	0.6	0
134	Functional Characterization of the Type 1 VWD Candidate VWF Gene Variants: P.M771I, p.L881R, p.P1413L, and p.Q1475X. Blood, 2012, 120, 97-97.	0.6	0
135	Platelet-Mediated Mechanical Tensile Force Influences ADAMTS13 Localization and Regulation Of Thrombus Development At The Site Of Platelet Accumulation. Blood, 2013, 122, 454-454.	0.6	0
136	Myeloid-Derived Suppressor Cell (MDSC) Dynamics In FVIII-Exposed Hemophilia A Mice: Novel Therapeutic Implications. Blood, 2013, 122, 3569-3569.	0.6	0
137	VWF-FVIII Interactions Influence Hemostatic Thrombus Stability in Murine Models of Hemophilia Î‘ and Type 2N VWD. Blood, 2016, 128, 1403-1403.	0.6	0
138	The Highly Prevalent Deletions in F8 Intron 13 Found in French Mild Haemophilia a Patients Result of Both Founder Effect and Recurrent De Novo Events. Blood, 2018, 132, 2489-2489.	0.6	0
139	COVIDâ€19 â€" Two years in. Journal of Thrombosis and Haemostasis, 2021, 19, 2905-2905.	1.9	0
140	Scientific method and the COVID pandemic. Journal of Thrombosis and Haemostasis, 2022, 20, 547-548.	1.9	0
141	Changes and challenges in the new year. Journal of Thrombosis and Haemostasis, 2022, 20, 1-1.	1.9	0
142	Investment in the future of thrombosis and hemostasis science. Journal of Thrombosis and Haemostasis, 2022, 20, 1033-1033.	1.9	0